Ipriflavone and low doses of estrogens in the prevention of bone mineral loss in climacterium

Melis, Gian Benedetto; Paoletti, Anna Maria; Bartolini, R; Balducci, Massimo; Massi, Giambattista; Bruni, Vincenzina; Becorpi, Angelamaria; Ottanelli, Serena; Fioretti, P.; Gambacciani, Marco; Spinetti, A.; D'Antona, N; Leo, Vincenzo De; Agnusdei, D.; Camporeale, A.; Gennari, C

doi:10.1016/0169-6009(92)90866-c

Cited by 28 publications

(4 citation statements)

References 14 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…30 Combinations included ipriflavone 600 mg/day with either CEE 0.625 mg/day, 28 CEE 0.3 mg/day, 27,29 or CEE 0.15 mg/day. 29 Although the study populations varied (early postoopherectomy in one, healthy postmenopausal in another, and postmenopausal with osteoporosis risk factors in the third), all three trials suggested a benefit of the combination treatment over CEE 0.3-0.625 mg/day alone. Additionally, two other recent trials suggest a preventive benefit of CEE combined with either calcitriol or risedronate.…”

Section: Discussionmentioning

confidence: 99%

“…For example, ipriflavone is a synthetic isoflavone that has been combined with estrogen replacement in three trials. [27][28][29] Isoflavones are the principal phytoestrogens (plant estrogens) of soy and have weak estrogenic activity. 30 Combinations included ipriflavone 600 mg/day with either CEE 0.625 mg/day, 28 CEE 0.3 mg/day, 27,29 or CEE 0.15 mg/day.…”

Section: Discussionmentioning

confidence: 99%

“…[27][28][29] Isoflavones are the principal phytoestrogens (plant estrogens) of soy and have weak estrogenic activity. 30 Combinations included ipriflavone 600 mg/day with either CEE 0.625 mg/day, 28 CEE 0.3 mg/day, 27,29 or CEE 0.15 mg/day. 29 Although the study populations varied (early postoopherectomy in one, healthy postmenopausal in another, and postmenopausal with osteoporosis risk factors in the third), all three trials suggested a benefit of the combination treatment over CEE 0.3-0.625 mg/day alone.…”

Section: Discussionmentioning

confidence: 99%

See 2 more Smart Citations

Combination Treatment of Osteoporosis: A Clinical Review

Crandall¹

2002

Journal of Women's Health & Gender-Based Medicine

View full text Add to dashboard Cite

The few trials including Food and Drug Administration (FDA)-approved medications suggest that 10 mg/day alendronate with estrogen (equivalent of 0.625 mg CEE daily) can increase BMD moreso than each medication given singly in postmenopausal osteoporotic women. Estrogen dose and type must be controlled in future trials. Long-term safety data are lacking. The utility of these combinations rests on whether bone density changes will translate into decreased fracture rates.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Combination Treatment of Osteoporosis: A Clinical Review

Crandall¹

2002

Journal of Women's Health & Gender-Based Medicine

View full text Add to dashboard Cite

show abstract

“…Numerous clinical trials have demonstrated IP's ability to slow the continual decline in bone mineral density (BMD) commonly observed after menopause. [1][2][3][4][5][6][7] Melis et al 8 demonstrated that IP may be as effective as estrogen in its ability to prevent bone loss, and a combination of the two treatments may improve the effects of hormone replacement therapy (HRT). IP has been shown to reduce the rate of bone breakdown by inhibiting osteoclast and stimulating osteoblast activity while apparently having no effect on breast or reproductive tissue.…”

Section: Introductionmentioning

confidence: 98%

The Effect of an Ipriflavone-Containing Supplement on Urinary N-Linked Telopeptide Levels in Postmenopausal Women

Halpner¹,

Kellermann²,

Ahlgrimm³

et al. 2000

Journal of Women's Health & Gender-Based Medicine

View full text Add to dashboard Cite

Osteoporosis is a significant health concern to our aging population. We report here the results of a pilot placebo-controlled trial of a dietary supplement containing ipriflavone, calcium, and vitamin D on a urinary marker of bone breakdown in postmenopausal women. Seven postmenopausal women not currently receiving hormone replacement therapy received either an ipriflavone-containing supplement or placebo for 3 months. Urinary N-linked telopeptides, a marker of bone breakdown, declined by 29% in those receiving the supplement, whereas an increase in this marker was observed in the group receiving the placebo. No changes were observed in salivary hormone measurements. Although our sample size was small, to the best of our knowledge, this is the first report that demonstrates changes in N-linked telopeptide levels as a result of consuming an ipriflavone-containing product. Our findings confirm those of other researchers that demonstrate the usefulness of ipriflavone at slowing the progression of bone loss and suggest that measuring N-linked telopeptides may be a useful tool to assess therapeutic efficacy.

show abstract

An Overview of Sports Supplements

Lockwood¹

Essentials of Sports Nutrition Study Guide

View full text Add to dashboard Cite

Ipriflavone and low doses of estrogens in the prevention of bone mineral loss in climacterium

Cited by 28 publications

References 14 publications

Combination Treatment of Osteoporosis: A Clinical Review

Combination Treatment of Osteoporosis: A Clinical Review

The Effect of an Ipriflavone-Containing Supplement on Urinary N-Linked Telopeptide Levels in Postmenopausal Women

An Overview of Sports Supplements

Contact Info

Product

Resources

About